TRCT
LABD icon

Tower Research Capital (TRC)’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Tower Research Capital (TRC)’s Portfolio LABD Stock Details LABD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113K Sell
6,908
-25,654
-79% -$486K ﹤0.01% 2087
2025
Q4 		$686K Buy
32,562
+14,710
+82% +$399K 0.02% 653
2025
Q3 		$722K Buy
17,852
+13,732
+333% +$795K 0.02% 652
2025
Q2 		$308K Buy
4,120
+1,927
+88% +$170K 0.01% 1397
2025
Q1 		$207K Buy
2,193
+448
+26% +$32.8K 0.01% 1356
2024
Q4 		$127K Sell
1,745
-6,354
-78% -$389K ﹤0.01% 2020
2024
Q3 		$473K Buy
8,099
+5,916
+271% +$359K 0.01% 905
2024
Q2 		$160K Sell
2,183
-730
-25% -$61.6K ﹤0.01% 2241
2024
Q1 		$212K Sell
2,913
-6,909
-70% -$577K 0.01% 1373
2023
Q4 		$952K Buy
9,822
+9,250
+1,617% +$1.8M 0.01% 887
2023
Q3 		$118K Sell
572
-15,004
-96% -$2.44M ﹤0.01% 1865
2023
Q2 		$2.24M Buy
15,576
+11,769
+309% +$1.76M 0.07% 209
2023
Q1 		$784K Sell
3,807
-11,980
-76% -$2.04M 0.03% 567
2022
Q4 		$2.72M Buy
15,787
+857
+6% +$176K 0.11% 126
2022
Q3 		$3.58M Buy
14,930
+3,603
+32% +$837K 0.06% 259
2022
Q2 		$4.41M Buy
11,327
+3,473
+44% +$1.74M 0.1% 172
2022
Q1 		$2.75M Buy
7,854
+53
+0.7% +$20.8K 0.03% 486
2021
Q4 		$2.01M Sell
7,801
-5,771
-43% -$1.33M 0.03% 409
2021
Q3 		$2.89M Buy
13,572
+11,056
+439% +$2.35M 0.07% 189
2021
Q2 		$486K Sell
2,516
-4,223
-63% -$947K 0.01% 1212
2021
Q1 		$1.47M Buy
6,739
+5,375
+394% +$1.04M 0.02% 589
2020
Q4 		$345K Buy
1,364
+579
+74% +$221K 0.01% 1288
2020
Q3 		$469K Sell
785
-2,096
-73% -$1.35M 0.01% 1744
2020
Q2 		$2M Buy
+2,881
New +$3.62M 0.08% 227
2020
Q1 		– Sell
-138
Closed -$341K – 3510
2019
Q4 		$341K Sell
138
-78
-36% -$277K 0.03% 402
2019
Q3 		$1.09M Buy
216
+194
+882% +$799K 0.08% 262
2019
Q2 		$81K Sell
22
-93
-81% -$392K 0.01% 1281
2019
Q1 		$424K Buy
115
+113
+5,650% +$547K 0.03% 696
2018
Q4 		$20K Sell
2
-87
-98% -$638K ﹤0.01% 1936
2018
Q3 		$436K Sell
89
-426
-83% -$2.06M 0.03% 559
2018
Q2 		$2.67M Buy
515
+244
+90% +$1.48M 0.15% 124
2018
Q1 		$1.98M Buy
271
+252
+1,326% +$1.75M 0.17% 90
2017
Q4 		$175K Sell
19
-27
-59% -$269K 0.02% 615
2017
Q3 		$435K Sell
46
-28
-38% -$338K 0.04% 303
2017
Q2 		$1.02M Buy
74
+8
+12% +$154K 0.12% 136
2017
Q1 		$1.39M Buy
66
+37
+128% +$914K 0.14% 59
2016
Q4 		$1.1M Buy
29
+23
+383% +$885K 0.12% 188
2016
Q3 		$194K Buy
+6
New +$281K 0.02% 500
2016
Q1 		– Sell
-2
Closed -$143K – 4560
2015
Q4 		$143K Buy
2
+1
+100% +$76.4K 0.02% 238
2015
Q3 		$113K Buy
+1
New +$70.8K 0.01% 496

Other funds holding LABD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCM
Capstone Capital Management Hong Kong $224M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Tower Research Capital (TRC)'s LABD Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Direxion Daily S&P Biotech Bear 3X ETF (LABD) stake by 79% in Q1 2026, selling an estimated $486K and leaving 6,908 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #2087.

Tower Research Capital (TRC) first reported a position in LABD in Q3 2015 and has held it in 40 quarters since. The position peaked at $4.41M in Q2 2022. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.

  • Tower Research Capital (TRC) held 6,908 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $113K as of Q1 2026.
  • Tower Research Capital (TRC) sold 25,654 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2026, an estimated $486K.
  • Direxion Daily S&P Biotech Bear 3X ETF made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2087 holding.
  • Tower Research Capital (TRC) first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q3 2015 and has held it in 40 quarters since.
  • Tower Research Capital (TRC)'s Direxion Daily S&P Biotech Bear 3X ETF position peaked at $4.41M in Q2 2022.
  • 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.